Navigation Links
Landauer, Inc. Reports Fiscal 2011 Fourth Quarter and Year End Results
Date:12/6/2011

GLENWOOD, Ill., Dec. 6, 2011 /PRNewswire/ -- Landauer, Inc. (NYSE: LDR), a recognized leader in personal and environmental radiation monitoring, outsourced medical physics services and high quality medical consumable accessories, today reported financial results for its fiscal 2011 fourth quarter and year ended September 30, 2011.

Fiscal 2011 Highlights

  • Revenue increased 5.3 percent to $120.5 million.
  • Gross profit grew 4.4 percent to $72.9 million on increased revenue and product mix.
  • Operating income increased $0.3 million to $34.9 million.
  • Net income increased 3.6 percent to $24.5 million, or $2.58 per diluted share.
  • Completed acquisition of IZI Medical Products in November.
  • Announced quarterly dividend rate of $0.55 for the first fiscal quarter of fiscal 2012 in November, providing an annual dividend rate of $2.20 consistent with 2011 levels.
  • The military issued orders totaling $14.5 million relating to the Company's initiatives during the fiscal year for shipments in fiscal 2012 and beyond.
  • "The results for this year demonstrate the balanced approach we are taking in the pursuit of new growth opportunities and managing resources effectively to produce steadily improving long-term performance in our core dosimetry business and new markets," stated Bill Saxelby, President and CEO of Landauer.  "During fiscal 2011 we made significant progress against our strategic priorities and we continue to see strong interest from the market for services that integrate our traditional occupational monitoring services with our Medical Physics offering."

    Saxelby added, "We successfully advanced our military initiative and received orders from the U.S. military for a program totaling $14.5 million during the fiscal year, which will be shared with our military partner. The Company's po
    '/>"/>

    SOURCE Landauer, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2011 Results
    2. Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC
    3. Landauer, Inc. Reports Fiscal 2011 Third Quarter Results
    4. Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2011 Results
    5. Landauer, Inc. Declares Regular Cash Dividend
    6. Landauer, Inc. Sets Date and Time for Announcement of Fiscal Second Quarter 2011 Results
    7. Landauer, Inc. Declares Regular Cash Dividend
    8. Landauer, Inc. Sets Date and Time for Announcement of Fiscal First Quarter 2011 Results
    9. Landauer, Inc. Declares Regular Cash Dividend
    10. Landauer, Inc. Sets Date and Time for Announcement of Fiscal First Quarter 2010 Results
    11. Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2009 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
    (Date:11/26/2014)... 26, 2014 China Nepstar Chain Drugstore Ltd. (NYSE: ... leading retail drugstore chain in China based on the ... financial results for the third quarter ended September 30, 2014. ... , Same store sales increased by 8.1% compared ... increased by 8.1% to RMB738.3 million (US$120.3 million) compared to ...
    (Date:11/24/2014)... 2014 Luoxis Diagnostics, Inc., a subsidiary ... announced the presentation of three clinical and preclinical ... broadly applicable and robust research tool capable of ... response to injury, illness, or stress.  In all ... Luoxis, academic and pharmaceutical research partners, RedoxSYS was ...
    Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 11Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5
    (Date:11/26/2014)... News) -- Parents need to take an active role ... warns. Parents must make sure sports-playing teens have ... Dodick, chair of the American Migraine Foundation and a ... Medicine in Scottsdale, Ariz. in an American Migraine Foundation, ... coach involved with teens sports needs to have appropriate ...
    (Date:11/24/2014)... From embedded sensors and biometrics to elite training ... take center stage at the FitnessTech Summit , presented ... 2015 International CES® , January 6, 2015 in Las Vegas ... The bond between fitness and technology is stronger than ever ... more about the human body. , “Fitness technology has become ...
    (Date:11/24/2014)... 2014 Global electrophysiology devices market ... 2020, according to a new study by Grand ... arrhythmias clubbed with growing global geriatric population base ... still in the budding stage, the electrophysiology devices ... rates in the recent times, with physicians increasingly ...
    (Date:11/24/2014)... (PRWEB) November 24, 2014 Volpara ... version 1.2 at the 100th Annual Meeting of ... 30-December 5, 2014 (RSNA Booth 1752 – South ... of VolparaAnalytics and the rest of its innovative ... and VolparaDoseRT, which enable personalized measurements of volumetric ...
    (Date:11/24/2014)... November 24, 2014 Residents of retirement ... in this year’s SENIORS GOT TALENT, an annual online ... From piano players to classic crooners, to seniors partying ... older adults are indeed living young. , “SENIORS GOT ... there’s a cash prize, has always been about highlighting ...
    Breaking Medicine News(10 mins):Health News:Parents Need to Take Lead on Teen Concussion Prevention 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 4Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 2Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 3Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 4Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 2Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 3
    ... ... Health , ... (PRWEB) October 11, 2009 – The YWCA’s Week Without Violence kicks off today, acting as ... need for trained social workers throughout the world. Those interested becoming community support workers can ...
    ... - Mentalympians(TM) announced today, on this World Mental Health ... based in Australia, Canada, New Zealand, Scotland and the ... found on www.mentalympians.org . , Mentalympians has been ... operated through a network of mental health consumer groups. ...
    ... ... MAN (renewman.com), the first male hormone treatment program in the U.S., continues to ... symptoms, including andropause. A common condition among men ages 35 and older, reNEW ... doctor that can test, diagnose and treat hormone deficiencies through safe, self-administered treatments. ...
    ... with mental, neurological, and substance use (MNS) disorders in low ... the mental health "treatment gap." This week PLoS ... helping to close the gap. The series coincides with ... Mental Health, a collaborative initiative of the London School of ...
    ... InfoLogix, Inc. (Nasdaq: IFLG ), a leading ... and commercial industries, today announced that it has retained ... based in West Conshohocken, PA to assist InfoLogix in ... negotiates financing transactions at virtually every level of the ...
    ... (MIS), best known for regulating in utero sexual differentiation in ... according to a new study published online October 9 in ... associated with breast cancer risk, Joanne F. Dorgan, Ph.D., MPH, ... conducted a prospective case-control study of 309 participants who were ...
    Cached Medicine News:Health News:YWCA's Week Without Violence Oct. 11-17 a Reminder That Community Support Workers Remain in High Demand 2Health News:World-first mental health media initiative announces inaugural Advisory Group 2Health News:Locate a Male Menopause Physician with reNEW MAN 2Health News:Locate a Male Menopause Physician with reNEW MAN 3Health News:Locate a Male Menopause Physician with reNEW MAN 4Health News:How should mental, neurological and substance use disorders be treated where resources are scarce? 2Health News:InfoLogix Announces News Related to its Recent Corporate Development Initiatives 2
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    Medicine Products: